<PAGE> 1
------------------------
OMB APPROVAL
------------------------
OMB Number: 3235-0145
Expires: 31-Aug-99
Estimated Average burden
hours per response
------------------------
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(AMENDMENT NO. _________)*
Invitrogen Corporation
- --------------------------------------------------------------------------------
(Name of Issuer)
Common Stock Par Value $.01
- --------------------------------------------------------------------------------
(Title of Class of Securities)
46185R 10 0
- --------------------------------------------------------------------------------
(CUSIP Number)
Check the following box if a fee is being paid with this statement [ ].
(A fee is not required only if the filing person: (1) has a previous
statement on file reporting beneficial ownership of more than five
percent of the class of securities described in Item 1; and (2) has
filed no amendment subsequent thereto reporting beneficial ownership of
five percent or less of such class.) (See Rule 13d-7).
*The remainder of this cover page shall be filled out for a reporting
person's initial filing on this form with respect to the subject class
of securities, and for any subsequent amendment containing information
which would alter the disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not
be deemed to be "filed" for the purpose of Section 18 of the Securities
Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of
that section of the Act but shall be subject to all other provisions of
the Act (however, see the Notes).
Sec 1745 (10-88)
Page 1
<PAGE> 2
CUSIP NO. 46185R 10 0 13G PAGE 2
1 NAME OF REPORTING PERSON S.S. OR I.R.S IDENTIFICATION NO.
OF ABOVE PERSON
TA/Advent VIII L.P. 04-3334380
Advent Atlantic & Pacific III L.P. 04-3299318
TA Venture Investors L.P. 04-3068354
2 CHECK THE BOX IF A MEMBER OF A GROUP*
(a) /X/
(b) / /
3 SEC USE ONLY
4 CITIZENSHIP OR PLACE OF ORGANIZATION
TA/Advent VIII L.P. Delaware
Advent Atlantic & Pacific III L.P. Delaware
TA Venture Investors L.P. Massachusetts
5 SOLE VOTING POWER
NUMBER OF TA/Advent VIII 731,215
Advent Atlantic & Pacific III L.P. 137,103
SHARES TA Venture Investors L.P. 14,624
6 SHARED VOTING POWER
BENEFICIALLY N/A
OWNED BY
7 SOLE DISPOSITIVE POWER
EACH TA/Advent VIII L.P. 731,215
Advent Atlantic & Pacific III L.P. 137,103
REPORTING TA Venture Investors L.P. 14,624
8 SHARED DISPOSITIVE POWER
WITH N/A
9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
TA/Advent VIII L.P. 731,215
Advent Atlantic & Pacific III L.P. 137,103
TA Venture Investors L.P. 14,624
10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
TA/Advent VIII L.P. 3.87%
Advent Atlantic & Pacific III L.P. 0.73%
TA Venture Investors L.P. 0.08%
12 TYPE OF REPORTING PERSON
Each entity is a Limited Partnership
SEE INSTRUCTION BEFORE FILLING OUT!
<PAGE> 3
ATTACHMENT TO FORM 13G PAGE 3
ITEM 1 (a) NAME OF ISSUER: Invitrogen Corporation
ITEM 1 (b) ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES:
1600 Faraday Avenue
Carlsbad, CA 92008
ITEM 2 (a) NAME OF PERSON FILING:
TA/Advent VIII L.P.
Advent Atlantic & Pacific III L.P.
TA Venture Investors L.P.
ITEM 2 (b) ADDRESS OF PRINCIPAL BUSINESS OFFICE:
c/o TA Associates
125 High Street, Suite 2500
Boston, MA 02110
ITEM 2 (c) CITIZENSHIP: Not Applicable
ITEM 2 (d) TITLE AND CLASS OF SECURITIES: Common
ITEM 2 (e) CUSIP NUMBER: 46185R 10 0
ITEM 3 IF THIS STATEMENT IS FILED PURSUANT TO RULES 13d-1 (b) OR 13d-2 (b),
CHECK WHETHER THE PERSON FILING IS A: Not Applicable
ITEM 4 OWNERSHIP
ITEM 4 (a) AMOUNT BENEFICIALLY OWNED: COMMON STOCK
------------
TA/Advent VIII L.P. 731,215
Advent Atlantic & Pacific III L.P. 137,103
TA Venture Investors L.P. 14,624
ITEM 4 (b) PERCENT OF CLASS PERCENTAGE
----------
TA/Advent VIII L.P. 3.87%
Advent Atlantic & Pacific III L.P. 0.73%
TA Venture Investors L.P. 0.08%
ITEM 4 (c) NUMBER OF SHARES AS TO WHICH SUCH PERSON HAS:
(I) SOLE POWER TO VOTE OR DIRECT THE VOTE: COMMON STOCK
TA/Advent VIII L.P. 731,215
Advent Atlantic & Pacific III L.P. 137,103
TA Venture Investors L.P. 14,624
(II) SHARED POWER TO VOTE OR DIRECT THE VOTE: N/A
(III) SOLE POWER TO DISPOSE OR DIRECT THE DISPOSITION: COMMON STOCK
TA/Advent VIII L.P. 731,215
Advent Atlantic & Pacific III L.P. 137,103
TA Venture Investors L.P. 14,624
(IV) SHARED POWER TO DISPOSE OR DIRECT THE DISPOSITION N/A
<PAGE> 4
PAGE 4
ITEM 5 OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS: Not Applicable
ITEM 6 OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON:
Not Applicable
ITEM 7 IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY THAT ACQUIRED
THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY:
Not Applicable
ITEM 8 IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP:
This schedule 13G is filed pursuant to Rule 13d-1 (c). For the
agreement of group members to a joint filing, see below.
ITEM 9 NOTICE OF DISSOLUTION OF GROUP: Not Applicable
ITEM 10 CERTIFICATION: Not Applicable
<PAGE> 5
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify
that the information set forth in this statement is true, complete and correct.
2/14/00
-------------------------
Date
/s/ Katherine S. Cromwell
-------------------------
Signature
Managing Director
-------------------------
Name/Title
<PAGE> 6
AGREEMENT FOR JOINT FILING
TA/Advent VIII L.P., Advent Atlantic and Pacific III L.P. and TA Venture
Investors L.P., hereby agree that TA Associates shall file with the Securities
and Exchange Commission a joint schedule 13G on behalf of the above-named
parties concerning their beneficial ownership of Invitrogen Corporation.
Dated:
TA/ADVENT VIII L.P.
By: TA Associates VIII LLC, its General Partner
By: TA Associates, Inc. its Manager
By:
Katherine S. Cromwell, Managing Director
ADVENT ATLANTIC & PACIFIC III L.P.
By: TA Associates AAP III Partners L.P., its General Partner
By: TA Associates, Inc. its General Partner
By:
Katherine S. Cromwell, Managing Director
TA VENTURE INVESTORS L.P.
By:
Katherine S. Cromwell, Managing Director
